More physicians being sued by patients they’ve never treated
Do doctors ever have “legal duty of care” in such cases? An AMA education session explored the issue.
Related Articles
Page Waterman Gallery and Framing – Page Waterman Gallery and Framing
Exceptionally Custom, Expertly Framed selecting it and showcasing your artwork to its best advantage. You have a wide range of treasured art and objects. And…
AstraZeneca announces $50 billion US investment
AstraZeneca announced that it will invest $50 billion in the U.S. by 2030, including a multi-billion-dollar manufacturing site in Virginia.
Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S. | Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jul. 21, 2025– Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Today,…
Google tapped billions of mobile phones to detect quakes worldwide — and send alerts
Nature – Study reveals how the tech behemoth is using the motions sensors on phones to expand quake warnings to more countries.
Dr. Nick Nurmohamed and Dr. C. Michael Gibson discuss: What We Thought Was Wrong: Evolution of the Approach to Evaluation and Treatment of Coronary Artery Disease – Clinical Trial Results
Disclosures: Sponsored by Cleerly, Women as One, and International Atherosclerosis
When AI Listens In: How Conversational Data Could Disrupt Medicine
When I began practicing medicine, use of the Internet or a smartphone could not have been imagined because neither existed.
Ozempic for addiction: How an elite rehab center is using GLP-1s to ‘obliterate’ all kinds of cravings
Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.
Dr. Fatima Rodriguez and Dr. C. Michael Gibson discuss: Atherosclerosis: Basic Concepts and Current Understanding – Clinical Trial Results
Sponsored by: Cleerly, Women as One and International Atherosclerosis
Zealand’s GLP-2 candidate shows early weight loss results
Zealand Pharma said that its obesity candidate that uses a unique mechanism led to notable weight loss in an early trial.